The prevalence of methadone-related overdose deaths is increasing worldwide and has been a topic of recent debate. Methadonerelated deaths, to this point, have not been systematically reviewed in the state of Vermont. All of the methadone-related fatalities from 2001 to 2006 (total, 76 cases), which were examined by the Vermont Office of the Chief Medical Examiner were retrospectively reviewed. The mean age of the decedents was 36 years (range, 16Y74 years), and 72% were male. The manners of death were classified as follows: 84% accident, 12% undetermined, and 4% suicide. The mean level of methadone was 457 ng/mL (range, 50Y3793 ng/mL). The substances causing death were determined to be methadone alone in 26 (34%), methadone with only other prescribed medications in 29 (38%), methadone with only illicit drugs (excluding tetrahydrocannabinol) in 13 (17%), methadone with both illicit and prescribed medications in 5 (7%), and methadone with ethanol in 3 (4%). The methadone was obtained by illegal diversion (sale, gift, or theft) in 67% of cases. In the remaining cases (33%), the methadone was obtained by physician_s prescription for chronic pain (60%), acute pain or injury (8%), methadone maintenance therapy for heroin dependence (8%), and unknown reasons (24%). The number of overdose deaths has increased 4-fold from 2001 (17 deaths) to 2006 (79 deaths). The proportion of methadone-related deaths has increased by 300% from 2001 (0.6% of reported deaths, 12% of overdose deaths) to 2006 (3% of reported deaths, 37% of overdose deaths). Methadone maintenance therapy for heroin dependence in our population comprises an insignificant number of the methadone-related deaths (3% of the decedents). In Vermont, the populations most at risk are those taking methadone for chronic pain and those obtaining diverted methadone for abuse. Education of clinicians regarding the increasing number of methadone-related deaths, the potential for abuse and diversion, and the pharmacokinetics of methadone may help halt this epidemic and reduce the number of fatalities from this drug.
T he number and prevalence of methadone-related deaths in the United States and worldwide has increased over the last decade. 1Y3 While this has been a topic of recent discussion, and forensic pathologists have noticed an increasing trend, methadone-related deaths to this point have not been systematically reviewed in the state of Vermont.
BACKGROUND
Heroin abuse and dependence began increasing in the post-World War II era. By the 1950s and 1960s, it had reached epidemic proportions, particularly in New York City. 4, 5 The heroin-related death rate during this time increased from 7.2 per 10,000 deaths in 1950 to 35.8 per 10,000 deaths in 1961. And by 1961, death related to heroin injection had become the leading cause of death in young adults in New York City, with a mean age of 29. 6, 7 It was because of these alarming figures that several independent researchers began exploring a substitution approach to heroin treatment. Methadone, or dolophine, a longacting agonist with a half life of 24 to 36 hours, was first synthesized in pre-World War II Germany for analgesia. In 1949, Isbell and Vogel at the US Public Health Hospital showed that methadone was the most effective substitution medication for the treatment of heroin dependence. 6, 8 The protocol was to discontinue methadone after a short taper. Follow-up studies in the 1950s and 1960s, however, showed a high relapse rate of over 90% once methadone was discontinued. 6 Methadone maintenance treatment (MMT) was studied intensively beginning in 1964 at The Rockefeller University by a research laboratory overseen by Nyswander and Dole. 9 They determined that the amount of daily methadone should be sufficient to relieve narcotic craving, block the effects of administrated heroin or other short-acting opioids, suppress the opioid abstinence syndrome for 24 to 36 hours, develop tolerance to the analgesic effects of methadone and develop tolerance to the euphoria, sedation, and other narcotic effects of methadone. 6,9Y11 Analysis of these signs and symptoms in a patient allowed establishment of a titrated daily maintenance dose. In the beginning, these studies were conducted in inpatients over weeks to months; however, studies evaluating inpatient versus outpatient methadone treatment in 1965Y1966 showed no significant difference in outcomes. 12 Thus, the outpatient methadone clinic model was adopted in 1966 for the expansion of MMT throughout the United States. 6 Since these fundamental studies, there have been several studies documenting the benefits of MMT. These benefits include the reduction of criminal activity, 13 reducing the costs of crime, 14 decreasing illicit drug use by opiate abusers, 15 improving social integration, 16 improving employment prospects, 17 and reducing the morbidity and mortality of opiate users. 18Y21 While this is a positive change, recent trends suggest that the increase in methadone use in some cases may be problematic.
The Office of Analysis and Epidemiology, under the US Department of Health and Human Services and the Centers for Disease Control and Prevention has identified recent trends in overdose and specifically methadone-related deaths between 1999 and 2004. 1 During this time period, methadone-related deaths have increased 390%. Methadone-related deaths have increased from 4% of all overdose/poisoning deaths to 13% of all overdose/poisoning deaths. The relative increase in methadonerelated overdose deaths from 1999 to 2004 was greater than for any other individual substance. The largest increase was noted in the 15 to 24 year age group, which was 11-fold higher in 2004 than in 1999. 1 These national trends are mirrored in the state of Vermont. It became apparent that there were an increasing number of methadone-related deaths in Vermont. Until this point, these deaths have not been systematically reviewed. The objective of this retrospective study was to review all of the methadonerelated deaths in Vermont over a 6-year period to identify trends, sources of methadone, and to characterize the populations at risk. From these data, it will be feasible to identify potential problem areas within the current system.
MATERIALS AND METHODS
There were 76 methadone-related deaths in the state of Vermont between the years 2001 and 2006. The cases were identified by searching the Vermont Office of the Chief Medical Examiner (OCME) database for cases in which methadone was identified in decedents_ blood and urine. Each case was identified by number and each corresponding file was read individually. Medical examiner and police investigation reports along with hospital medical records were included in the study. Furthermore, the toxicology report for each individual case was examined separately. About 76 cases were examined.
Autopsies had already been performed on the decedents as all deaths in which there is a suspicion of drug involvement have full autopsies. Toxicological examination by gas chromatography with mass spectrometry was performed on all specimens by a commercial reference laboratory to identify individual substances.
Cases chosen for the study included only drug overdose decedents who died in the state of Vermont between January 2001 and December 2006. Overdose deaths in which methadone was cited as a cause of death, alone or in combination with another illicit or prescribed drug were classified as methadonerelated deaths.
The classification of the cause of death was determined by a forensic pathologist. This determination was dependent on the circumstances of death, medical and scene background investigation, and the presence of a lethal level of methadone and/or its major metabolite, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine either alone or in combination with other drugs, as determined by the pathologist. The presence of the drug on its own was not enough to classify the case as a methadone-related death.
For all methadone-related deaths, we examined the gender, age, geographical location, medical history of individual and family, the indication of and dose for methadone prescription if available, other prescribed drugs, the blood levels of methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine, and other prescribed and illicit drug levels.
We identified the total cases as either belonging in a diversion group or in a prescription group. The methadone-related deaths attributed to diversion were determined by the absence of a physician_s prescription. If the individual had a prescription for any reason, including, but not limited to MMT, they were included in the prescription group.
Calculations and Trend Analysis
We calculated the mean and median age, mean and median levels of methadone, percent male decedents, manner of death, the number and percentages of deaths due to methadone only, methadone with illicit drugs, methadone with other prescription drugs (not necessarily prescribed to them), and methadone with alcohol.
Finally, we identified the total number of deaths and the total number of overdose deaths reported to the OCME in the state of Vermont between 2001 and 2006 for comparative analysis and to identify trends over time.
RESULTS
Of 4317 deaths reported to the OCME in the state of Vermont between 2001 and 2006, 336 were overdose deaths and 76 of those were attributed to methadone. Over this time period, there was a 4-fold increase in overdose deaths from 2001 (17 deaths) to 2006 (79 deaths). The number of methadonerelated deaths increased from 2 to 29 per year over the 6-year time period. The proportion of methadone-related deaths increased by 300% from 2001 (0.6% of reported deaths, 11.8% of overdose deaths) to 2006 (3.4% of reported deaths, 36.7% of overdose deaths) ( Table 1) .
Because we found the total number of reported deaths and overdose-related deaths to change significantly from 2001 to 2002, a separate analysis was performed looking at the same data from 2002 to 2006. Between 2002 and 2006, the total number of overdose deaths in Vermont rose from 47 (6.3% of reported deaths) to 79 (9.4% of reported deaths). The number of methadone-related deaths during this time increased from 8 (1.7% of reported deaths, 17.0% of overdose deaths) to 29 (3.4% of reported deaths, 36.7% of overdose deaths), representing a greater than 2-fold increase in methadone-related deaths in 5 years.
The mean age of the decedents was 36 years, the median was 35 years (range, 16Y74 years) and 55 (72%) were male. The mean level of methadone was 457 ng/mL (range, 50Y3793 ng/mL). The manners of death were classified as follows: 64 (84%) accident, 9 (12%) undetermined, and 3 (4%) suicide ( Table 2 ). The substances causing death were determined to be methadone alone in 26 (34%), methadone with only other prescribed medications in 29 (38%), methadone with only illicit drugs (excluding tetrahydrocannabinol) in 13 (17%), methadone with both illicit and prescribed medications in 5 (7%), and methadone with ethanol in 3 (4%) ( Table 3 ). The most frequent prescription drugs used in combination with methadone were benzodiazepines, antidepressants, and other opioids. The methadone was obtained by illegal diversion (sale, gift, or theft) in 51 (67%) cases. In the remaining 25 (33%) cases, the methadone was obtained by physician_s prescription for chronic pain in 15 (60%), acute pain or injury in 2 (8%), methadone maintenance therapy for heroin dependence in 2 (8%), and unknown reasons in 6 (24%) ( Fig. 1, Table 3 ).
DISCUSSION
The prevalence of methadone-related overdose deaths is increasing in the state of Vermont. This echoes a similar increase throughout the entire United States. 1 The number of overdose deaths in our state has increased by over 4-fold during the time between 2001 and 2006, and over 2-fold in the years from 2002 to 2006. The number of methadone-related deaths has increased over 14-fold, from 2 to 29 per year in 2001 and 2006, respectively (Fig. 1) . The proportion of overdose deaths that are methadone-related has similarly increased from 12% to 37% of overdose deaths between 2001 and 2006, an increase of over 300% in 6 years. In 2006, methadone-related deaths comprised 3% of the total deaths reported to the OCME for the entire state. Interestingly, none of these deaths was associated with the state_s outpatient MMT programs. It is clear that there is a public health problem and it is essential to attempt to understand why methadone-related deaths are steadily climbing.
The most common substances causing death in our population were methadone alone or in combination with other prescription drugs (34% and 38%, respectively). The most frequent prescription drugs were benzodiazepines, other opioids, and antidepressants. This is not surprising as there are many articles that indicate a synergistic respiratory depressant effect of methadone and other central nervous system depressants. Corkery et al discuss the fact that most methadone deaths occur as a result of respiratory depression. They argue that this is more likely to occur when used in combination with other opiates, alcohol, or benzodiazepines. 22 Others have advertised the particular danger of alcohol and benzodiazepines with methadone. 3,23Y25 As a result of such reports of overdose and death associated with concurrent benzodiazepine use, in 2006 the Federal Drug Administration issued a public health advisory against using other drugs with methadone. 26 In addition, Roxane Laboratories, Inc. added precautionary statements against using benzodiazepines with methadone. 27 MMT programs in Vermont were shown to be safe and effective in our study; patients in these programs comprise a negligible number of the methadone-related deaths in the state. Over the 6-year time period, only 2 of the 76 decedents (3%) were enrolled in a methadone maintenance program at the time of death. One of the decedents was in an inpatient facility receiving treatment for heroin dependence and an eating disorder, and the other was enrolled in an outpatient methadone clinic in Massachusetts and died in Vermont, having received takeaway doses for a vacation. Thus, strictly speaking, there have been no methadone-related deaths involving patients enrolled in outpatient MMT in Vermont between 2001 and 2006. Rather, it appears the populations most at risk are those obtaining diverted methadone for abuse (67% of the total decedents) and those taking methadone for chronic pain (20% of the total decedents). There may be several as of now unidentified reasons for the increase in both methadone abuse and methadone-related deaths. However, there are 3 compelling reasons that will be discussed here. One is the relation of methadone-related deaths to methadone maintenance programs. Although this has been found to be negligible in Vermont, a significant proportion of methadone-related deaths in other states and abroad have been in those in maintenance programs. 3, 25, 28, 29 Second, is an increase in the use of methadone as a treatment for chronic and acute pain. Finally, the increase in prescription use has had the unintended consequence of significant illegal drug diversion. The latter 2 explanations account for at least 90% of methadonerelated deaths in the state of Vermont. Williamson et al has explored the safety of methadone prescribing in South Australia due to an increase in methadone prescribing for chronic pain. They found that their MMT program was generally safe, as shown by a decline in mortality despite higher doses and increased availability of takeaway doses. This was attributed to the fact that at higher doses, the opioid craving is decreased, and thus patients are less likely to seek other drugs. In addition, they found that the increase in prescribing methadone for chronic pain was the likely source of the large problem of illegal diversion they are experiencing. 3 However, some studies suggest MMT programs contribute to a significant proportion of the methadone-related deaths. Gagajewski and Apple found that 34.7% of decedents in Minnesota between 1992 and 2002 were enrolled in MMT programs at the time of death while 39% were illicit users (diverted methadone) and 15% were chronic pain patients. 28 Shah et al looked at methadone-related deaths in New Mexico between 1998 and 2002. They found that at least 21.7% of the total decedents were in MMT programs and 18.9% had physician prescriptions for chronic pain. Only 7.7% of the decedents in New Mexico had definitively obtained diverted methadone. 29 From these data and from our own study, it is apparent that the amount of drug diversion, chronic pain-related and MMT-related deaths varies with geography. This likely is dependent on several factors intrinsic to the area. For example, the population and the prevalence of opioid dependence, the policies of the MMT clinics regarding dosing, takeaways and patient follow-up, the local climate for physician prescribing of methadone for chronic pain, and the amount of demand for drug diversion will inevitably change in different areas, thus making it important to study and understand one_s own population and risk stratification.
Vermont is a small state with a relatively homogeneous population. There are 3 main methadone clinics with 1 mobile unit and plans for a fourth clinic to open soon. Our clinics have strict patient follow-up and limit the number of takeaways that are available to patients. The state program guidelines are significantly more restrictive than the federal guidelines on takeaways. Takeaways are a privilege of long-term, stable patients. It is unclear why Vermont has had no MMT-associated methadone deaths over the study period while other similar studies in other states have shown rates above 20% of all methadone-related deaths over comparable study periods. Possible explanations are the restrictions on takeaway doses, a smaller population and/or closer follow-up.
There are 2 significant limitations of this study. One is the difficulty in obtaining information regarding the sources of methadone. We rely on the assistant medical examiner and police reports as well as medical records when they are available. This is often not sufficient to exactly categorize the data and may have resulted in an overestimate of the amount of drugs obtained via diversion. A second possible confounder in our data is a result of a change in leadership within the OCME during the study period. This change resulted in an increase of the number of autopsies performed by the staff. The numbers of overdose deaths from 2001 may be falsely low which may have resulted in an overestimate of the rate of increase of methadone-related deaths. For this reason, a second analysis was performed, looking at the increase in methadone-related deaths from 2002 to 2006. This increase, although smaller, still represented a greater than 2-fold increase in methadone-related deaths during this time period. This figure is likely a more representative change, although it is impossible to state this with certainty.
Despite the limitations of the study, it is clear that methadonerelated deaths are increasing at a rapid rate in Vermont, as in other states in New England and in the United States as a whole. Our focus in Vermont should turn to further exploring our population at risk to determine what we can do to eliminate the growing problem. As stated above, in many cases the source of methadone is unknown, therefore it is difficult to determine to what extent diversion is a significant problem. Our data suggest it to be an important factor in Vermont. The increase in prescriptions for chronic pain is an additional area to investigate for possible adjustments. Education of clinicians regarding the increasing number of methadone-related deaths, the potential for abuse and diversion, and the pharmacokinetics of methadone may help halt this epidemic and reduce the number of fatalities from this drug.
